CYP19A1 and breast cancer: A phase II randomized controlled trial of 80 women with breast cancer not on aromatase inhibitors but with a history of BSO demonstrated a mean reduction in bone mineral density of 8.5% in the lumbar spine and 5.7% in the hips over 18 months, which translates to an increased risk of fracture [38].